Shockwave Medical, Inc. - Common Stock (NQ:SWAV)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, May 30, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Shockwave Medical, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

2 Beaten-Down Growth Stocks to Buy Now Before They Start Soaring Again ↗

February 18, 2023

After falling 73% and 38% from their previous peaks, these beaten-down growth stocks are trading at sensible valuations.

Via The Motley Fool

5 Analysts Have This to Say About ShockWave Medical ↗

February 17, 2023

Via Benzinga

Shockwave Medical Just Tripled Profit Expectations, Delivering 991% Growth ↗

February 17, 2023

The company also beat sales expectations, meeting the high end of its outlook.

Via Investor's Business Daily

Shockwave Medical Shares Gain As Q4 Earnings Surpass Wall Street Expectations ↗

February 17, 2023

Via Benzinga

ShockWave Medical (SWAV) Q4 2022 Earnings Call Transcript ↗

February 17, 2023

SWAV earnings call for the period ending December 31, 2022.

Via The Motley Fool

Shockwave Medical Reports Fourth Quarter and Full Year 2022 Financial Results

February 16, 2023

From Shockwave Medical, Inc.

Via GlobeNewswire

Earnings Scheduled For February 16, 2023 ↗

February 16, 2023

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...

Via Benzinga

ShockWave Medical's Earnings Outlook ↗

February 15, 2023

Via Benzinga

Where ShockWave Medical Stands With Analysts ↗

January 26, 2023

Via Benzinga

ShockWave Medical Earnings Perspective: Return On Capital Employed ↗

December 01, 2022

Via Benzinga

3 Mid-Cap Earnings Plays to Watch This Week

February 14, 2023

Mid-caps could continue to be the hot hand for traders and investors alike. Keep an eye on these three upcoming earnings reports.

Via MarketBeat

Topics Economy

Updated SCAI Guidance Includes Coronary IVL as a Treatment Option in All U.S. Catheterization Labs Regardless of Surgical Backup Status

January 31, 2023

Guidance Expands Number of Hospitals that Can Access IVL to Include Sites Where Calcium Modification Tools Were Previously Not Recommended

From Shockwave Medical, Inc.

Via GlobeNewswire

3 Pharma Stocks That Will Mint Millionaires ↗

January 30, 2023

These pharma stocks all have excellent risk-reward ratios and the companies have developed treatments that could easily become blockbusters.

Via InvestorPlace

Mergers and Acquisitions in 2023 Off To A Strong Start

January 26, 2023

Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.

Via MarketBeat

3 Beaten-Down Growth Stocks That I'm Loading Up On in 2023 ↗

January 21, 2023

These stocks are all down by at least 42% from their all-time highs despite impressive performances from their underlying businesses.

Via The Motley Fool

Neovasc (NASDAQ: NVCN) (TSX: NVCN) Enters into Agreement to be Acquired by Shockwave Medical (NASDAQ: SWAV) for $100 Million & CVR

January 17, 2023

Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) is engaged as a specialty medical device company, which is focused on the development,

Via Spotlight Growth

Why Neovasc Shares Are Trading Higher Today ↗

January 17, 2023

Neovasc Inc. (NASDAQ: NVCN) shares are trading higher after ShockWave Medical, Inc. (NASDAQ: SWAV) announced it would acquire the company.

Via Benzinga

Shockwave Medical Seeks To Bolster Its Cardiovascular Disease Portfolio With Neovasc Acquisition ↗

January 17, 2023

Via Benzinga

Shockwave Medical Announces Agreement to Acquire Neovasc

January 17, 2023

From Shockwave Medical, Inc.

Via GlobeNewswire

How Doug Godshall Ignited The Spark At Shockwave ↗

January 12, 2023

ShockWave Medical CEO Doug Godshall says successful companies don't follow a formula.

Via Investor's Business Daily

Shockwave Medical Provides Quarterly Earnings Release Dates for 2023

January 04, 2023

From Shockwave Medical, Inc.

Via GlobeNewswire

2 Elite Growth Stocks Ready for a Bull Run in 2023 ↗

December 14, 2022

It's going to take more than a recession to stop these two from delivering outsized gains to patient investors.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022 ↗

December 12, 2022

Via Benzinga

Nasdaq Bear Market: 3 Unstoppable Growth Stocks to Buy at Knocked-Down Prices ↗

November 27, 2022

The road ahead of these businesses is a lot smoother than you'd think by looking at their stock prices.

Via The Motley Fool

7 Index Funds to Buy to Retire a Millionaire ↗

November 23, 2022

Although the market shows signs of improvement, the waters are still choppy enough for investors to focus on index funds to buy.

Via InvestorPlace

3 Beaten-Down Growth Stocks That Billionaires Are Buying With Both Hands ↗

November 23, 2022

Some of the world's most successful investors can't get enough of The Trade Desk, Shockwave Medical, and SoFi Technologies.

Via The Motley Fool

Shockwave Medical to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 22, 2022

From Shockwave Medical, Inc.

Via GlobeNewswire

$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years ↗

November 21, 2022

Long-term investors should consider the high upside of these growth stocks.

Via The Motley Fool

InMode Stock Shows Improved Technical Strength; Hits Key Technical Threshold ↗

November 16, 2022

The Relative Strength (RS) Rating for InMode stock moved up into a higher percentile Wednesday, as it got a lift from 64 to 78.

Via Investor's Business Daily

Shockwave Medical Publishes Inaugural ESG Report

November 16, 2022

From Shockwave Medical, Inc.

Via GlobeNewswire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.